1. Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation (Resolution 13) Ad Hoc Disease Transmission Advisory Committee (DTAC) Committee November 12-13, 2014

2.  June 2013- US Public Health Service released new PHS Guideline that now include Hepatitis B (HBV) and Hepatitis C (HCV) in addition to HIV  The Final Rule, §121.4 (OPTN policies: Secretarial review and appeals.) notes that the OPTN Board is responsible for developing policies consistent with recommendations of the CDC to test potential organ donors and follow transplant recipients to prevent the spread of infectious disease.  Current policies are not consistent with new PHS Guideline The Problem

3. #4- Promote Transplant Patient Safety Improve communication between OPOs and tx hospitals Increase capacity to identify patient safety issues #5- Promote Living Donor Safety Develop policy for medical/social evaluation Strategic Plan

4.  Align OPTN policy with 2013 PHS Guideline to meet Final Rule requirements  Enhance transplant recipient and living donor safety through updates to donor and recipient testing, informed consent, and vessel storage Goal of the Proposal

5. OPOsTx HospitalsLD Recovery Programs Store samples for serology and NAT for 10 yrs Develop and implement written protocol for post-tx testing for HIV/HBV/HCV (unless + pre-tx) Complete testing for the HIV/HBV/HCV as close to organ recovery as possible but <28 days No donor med/soc = increased risk Clarify informed consent policies - 15.3 HIV NAT or Ag/Ab combo for increased risk donors Cannot store HCV Ab or NAT pos or HBsAg or NAT pos extra vessels HCV NAT for ALL donors How Proposal Achieves its Goals

6.  HIV, HBV, and HCV NAT data collection fields in DonorNet® for deceased organ donors  Fields must display on DonorNet® and DonorNet® mobile  Serologies tab where they will reside renamed “Viral Detection”  HBV and HCV NAT screening criteria all organ match runs for all organs for deceased and living donors  Adds fields to the Waiting List for candidates  HIV, HBV, and HCV NAT data collection fields in Tiedi (Transplant Recipient Registration)  Additional NAT fields on LDR/DDR already being implemented as part of OMB project Programming Includes:

7. OPTN Committees Professional Societies Government Ex Officio DTACAOPOHRSA Living DonorASTFDA OPOASTS Operations & Safety NATCO Joint Subcommittee Composition SRTR invited, but did not participate. Representatives received all emails and open invite to attend as desired.

8.  Joint Subcommittee completing comprehensive review of Guideline’s 34 recommendations to determine:  Is the PHS recommendation covered by the Final Rule?  Is there policy already in place to address this? Does it need to be changed?  Should there be policy in place to address this, or should it remain a PHS recommendations? Proposal Development

9.  Strong agreement on addressing the 34 PHS recommendations and subsections within joint subcommittee and DTAC with one exception  Split vote on this topic from both groups… HCV nucleic acid testing (NAT) for ALL organ donors  Committee unanimously supported HIV and HCV NAT for increased risk donors, but could not come to agreement on universal HCV NAT Proposal Development

10.  The Final Rule, §121.4, notes that the OPTN Board of Directors is responsible for developing policies that are consistent with recommendations of the Centers for Disease Control and Prevention (CDC) to test potential organ donors and following transplant recipients to prevent the spread of infectious disease. Why is this an issue?

11. Public Comment Response Tally Type of Response Response Total In Favor In Favor as Amended Opposed No Vote/ No Comment/ Did Not Consider Individual29 22 (76%) 0 5 (17%) 2 Regional11 10 (91%) 1 (9%) 00 Committee19 6 (32%) 0 1 (5%) 12 Public Comment Feedback

12. ASTS Oppose due to universal HCV NAT requirement AST Oppose due to universal HCV NAT requirement NATCO Supports policy as written Professional Society Feedback

13. Several themes arose in reviewing feedback, and are outlined in detail on page 45 of the briefing paper, Exhibit A,in the DTAC’s board report. Comment Themes

14. Issues RaisedDTAC Comments Desire for standardization of NAT across platforms Guidance on how to proceed with initial positive (e.g. Triplex) How to proceed with possible false positive tests Challenging, but outside of OPTN purview. Thresholds for pos test results are set by industry and FDA. OPOs and tx centers should work closely with their labs and carefully review FDA guidance, testing package inserts NAT Concerns

15. Issues RaisedDTAC Comments Concerns related to access to NAT in some donor service areas. Could a NAT requirement lead to delayed donation or lost donors? Most OPOs have capacity to perform NAT A variety of process issues could result in delayed or lost donors NAT Concerns

16. YearHIV NATHBV NATHCV NAT 200844/58 (76%)20/58 (34%)40/58 (69%) 201056/57 (98%)43/57 (75%)55/57 (97%) OPO NAT Survey Results OPOs performing NAT for screening of potential deceased organ donors OPOs performing NAT for screening of all potential deceased organ donor, regardless of risk status YearHIV NATHBV NATHCV NAT 200830/58 (52%)14/58 (24%)28/58 (48%) 201039/57 (68%)30/57 (53%)39/57 (68%)

17. Issues RaisedDTAC Comments Increased false positives in low prevalence population with organ wastage (e.g. pediatric donors) OPO Committee supported universal HCV NAT, suggesting: danger in assuming that a sub-group of potential donors be assumed as “no increased risk” and allow for exemption from testing requirements. Final Rule does not allow for the exclusion of any specific group NAT Concerns

18.  Proportion of false positives depends on incidence in population  Further testing to clarify initial results rarely practical in deceased donors  Labs and test package inserts report an extremely low incidence of false positive rates.  9179 NAT (HIV/HCV) runs in organ or tissue donors  0.9% initially reactive but not repeatable  0.04% reactive but not discriminated  0.001% inhibitors and could not be amplified  3 (0.03%) NAT reactive and seronegative for HIV-1, HCV False positive NAT results Personal communication, Marek Nowicki, Nat Institute of Transplantation

19. HCV donor-derived infection Jan 2008 to October 2013 DTAC Experience with Donor Hepatitis C Testing; WTC 2014

20.  Timeline for implementation: OPOs and transplant hospitals need time to develop new internal procedures and testing protocols.  Hemodialysis as an increased risk factor for HCV only  Education materials for patients considering increased risk organs  How to handle recipient consent if potential living donor meets increased risk criteria Additional Comment Themes

21. Product Policy Programming Related education Target Population Impact: Deceased and Living Donors Transplant Candidates and Recipients Total IT Implementation Hours Total Overall Implementation Hours Overall Project Impact 4,950/17,885 4,500/10,680

22.  Added clarification that HIV NAT is not required when dialysis is only risk factor  For living and deceased donors  Modifications to nomenclature for viruses to be consistent between living and deceased donor language  Addition to include appropriate living donor reference since it applies to living and deceased donors Post-Public Comment Modifications

23. 2.9Required Deceased Donor Infectious Disease Testing e. Hepatitis C ribonucleic acid (RNA) by donor screening or diagnostic nucleic acid test (NAT) If a deceased donor is identified as being at increased risk for HIV, HBV, and HCV transmission according to the U.S. Public Health Services (PHS) Guideline, testing must also include HIV ribonucleic acid (RNA) by donor screening or diagnostic NAT or HIV antigen/antibody (Ag/Ab) combination test. This does not apply to donors whose only increased risk factor is receiving hemodialysis within the preceding 12 months, as they are at risk only for HCV according to the U.S. Public Health Services (PHS) Guideline. Proposed Amendment to Language (lines 90 and 97, page 24 of book)

24.  RESOLVED, that additions and modifications to Policies 2.2 (OPO Responsibilities), 2.4 (Deceased Donor Medical and Behavioral History), 2.7.B (Informing Personnel), Table 14-2 (Requirements for Living Kidney Donor Medical Evaluations) with the exception of NAT- related requirements, 15.3 (Informed Consent of Transmissible Disease Risk), 15.3.A (Deceased Donors with Additional Risk Identified Pre-transplant), 15.3.B (Deceased Donor at Increased Risk for Transmission of Blood-borne Pathogens), and 16.7.B (Vessel Storage) as set forth in Exhibit A, are hereby approved, effective February 1, 2015. and… Resolution 13 (page 22)

25.  FURTHER RESOLVED, that additions and modifications related to donor nucleic acid testing (NAT) requirements in Policy 2.9 (Required Deceased Donor Infectious Disease Testing) and Table 14-2 (Requirements for Living Kidney Donor Medical Evaluations) as set forth in Exhibit A, are hereby approved, effective pending programming and notice to the OPTN membership. Resolution 13 (page 22)

26. Thank you! Daniel Kaul, MD, Committee Chair kauld@med.umich.edu kauld@med.umich.edu Shandie Covington, Committee Liaison shandie.covington@unos.org shandie.covington@unos.org Questions?